DrugPatentWatch Database Preview

Details for Patent: 7,320,976

Which drugs does patent 7,320,976 protect, and when does it expire?

Patent 7,320,976 protects COMBIGAN and is included in one NDA.

This patent has twenty-two patent family members in nineteen countries.

Summary for Patent: 7,320,976

Title:	Combination of brimonidine and timolol for topical ophthalmic use
Abstract:	Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.
Inventor(s):	Chang; Chin-Ming (Tustin, CA), Beck; Gary J. (Fullerton, CA), Pratt; Cynthia C. (Mission Viejo, CA), Batoosingh; Amy L. (Mission Viejo, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	10/685,941
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,320,976
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 7,320,976

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Allergan	COMBIGAN	brimonidine tartrate; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	021398-001	Oct 30, 2007		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 7,320,976

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
8,133,890	Combination of brimonidine and timolol for topical ophthalmic use	➤ Sign Up
8,748,425	Combination of brimonidine and timolol for topical ophthalmic use	➤ Sign Up
7,030,149	Combination of brimonidine timolol for topical ophthalmic use	➤ Sign Up
7,642,258	Combination of brimonidine and timolol for topical ophthalmic use	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 7,320,976

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003228480	➤ Sign Up
Brazil	0302584	➤ Sign Up
Canada	2440764	➤ Sign Up
China	100558364	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 7,320,976

For more information try a trial or see the plans and pricing